

Pharmacy BULLETIN BOARD

Retail Issue ■ Monday February 7, 2011

STERIMAX INC.

AcetaZOLAMIDE for Injection USP 500 mg now available!

SteriMax Inc. is pleased to announce the launch of **AcetaZOLAMIDE for Injection USP 500 mg** (DIN 02358328, UPC 834324010007).

Once available only through the Special Access Program (SAP), AcetaZOLAMIDE for Injection USP is now available for sale at SteriMax.

AcetaZOLAMIDE for Injection USP is indicated for adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

AcetaZOLAMIDE for Injection USP is available for intravenous use, and is supplied as a sterile powder requiring reconstitution.

To order, please contact McKesson (item number 001127) or SteriMax Inc. customer service at 1-800-881-3550.



VALEANT
Valeant Canada

WELLBUTRIN® SR SUPPLY NOW AVAILABLE

Product	DIN #
WELLBUTRIN® SR 150 mg (bupropion hydrochloride SR)	02237825

Please be advised that Valeant Canada now has supply of WELLBUTRIN® SR 150 mg. We apologize for any inconvenience this back order may have caused.

If you have any questions regarding WELLBUTRIN® SR 150 mg or any other Valeant Canada products, please contact our Customer Service at:

Phone: 1-800-361-4261
Fax: 1-800-361-4266



HUMBER
Conference Services

Attention Pharmacy Technicians

Don't miss the 29th Annual Pharmacy Technicians Conference
February 26, 2011

Presented by Humber Institute of Technology & Advanced Learning
North Campus in Toronto, ON

Join your colleagues, industry suppliers and dynamic presenters at this premier educational event of the year.

Program information and online registration is available at pharmacy.humber.ca or for additional information contact leah.barclay@humber.ca. Registration closes on February 18.



FORMULARY UPDATE

QUEBEC – LIST OF MEDICATIONS

Effective immediately, **VAL-VANCO™ (Sterile Vancomycin Hydrochloride USP)** will be included in the RAMQ List of approved Medications.

500 mg and 1 g

Box of 10 vials

VAL-VANCO can be ordered from your local wholesaler.

UPC	DIN	Format	Mc Kesson	K&F	Ameri-source Bergen	Mc Mahon
8 7154700072 9	02342855	500 mg	983049	112605	VA00072	137596
8 7154700073 6	02342863	1 g	983155	112606	VA00073	136754

For more information, please contact Valeo Pharma Inc. at 1 866 694-0150.



VALEO PHARMA



STERIMAX INC.

OrfenAce Now Available in Convenient 10 pack Blister!

SteriMax Inc. is pleased to announce that OrfenAce (Orphenadrine Citrate) 100mg is now available in a convenient 10 pack Blister. (DIN 02047535 UPC 834324100258)

Once available ONLY in a bottle of 100, OrfenAce is now also available in a convenient 10 pack blister at SteriMax Inc.

OrfenAce is indicated for the relief of acute muscle spasm.

- **The ONLY IMMEDIATE RELEASE Orphenadrine Citrate in Canada**
- **Same dosing as extended release Orphenadrine Citrate: 1 tablet, twice/day**
- **Listed on the Quebec Formulary (RAMQ)**

Product	DIN	Tabs/Bottle	UPC
OrfenAce Blister	02047535	10 Tablets	834324100258
OrfenAce 100mg	02047535	100 Tablets	834324000206

To order, please contact your preferred wholesaler or SteriMax customer service at 1-800-881-3550.

Available at all major wholesalers

AmerisourceBergen	ST10025
Kohl & Frish	114848
McKesson	003898

OrfenAce
The Ace of muscle relaxants!

STERIMAX INC.**Dairy Free re-named to LactoMax and New Ultra Strength Launched!**

SteriMax Inc. is pleased to announce that we have changed the name of Dairy Free and Dairy Free Extra Strength to LactoMax and LactoMax Extra Strength.

The ingredients, formula, quality and UPC codes remain the same. Only the name has changed.

As part of this update, we have also launched LactoMax Ultra Strength in a bottle of 40 tablets + 10 bonus tablets.

Item	Strength	Tabs/bottle	NPN	UPC
LactoMax	3000 FCCLU	100	02017512	834324000107
LactoMax Extra Strength	4500 FCCLU	80	02224909	834324000114
LactoMax Ultra Strength	9000 FCCLU	40 + 10 bonus	80017813	834324027005

To order, please contact your preferred wholesaler or SteriMax customer service at 1-800-881-3550.

Wholesaler Item Codes				
Item	Amerisource Bergen	Kohl & Frisch	McKesson	Procurity
LactoMax	MJ00107	90559	965012	83432400010
LactoMax Extra Strength	MJ00114	90558	818187	
LactoMax Ultra Strength	MJ02700	113523	000963	avail. in January

LactoMax offers value to the Pharmacy and the consumer to the Max !

**Are you aware?**

Please visit

www.abuse-diversion.com

for an online CCCEP/DPQ-accredited learning opportunity.

"Learn to safeguard yourself, your patients and your community."

This program is supported by an educational grant from:



abuse@diversion

FERRING
PHARMACEUTICALS**NEW DISTRIBUTOR FOR hCG (PPC)**

Ferring Pharmaceuticals Canada, is pleased to announce the immediate availability of hCG (PPC): **Human Chorionic Gonadotropin** for injection.

Going forward in 2011, Ferring Pharmaceuticals will become the exclusive distributor of hCG (PPC) across Canada.

Ferring's Product code : 451

DIN : 02247459

UPC: 629336250219

Contents of 1 box:

1 vial containing 10,000 USP units
hCG (Chorionic Gonadotropin for injection)
1 vial containing sterile diluent
(10 ML Bacteriostatic water for injection USP)

Cost: \$ 72.00

For further information, please contact Ferring Pharmaceuticals Canada at 1-800-263-4057.

■ **FROM THE NEWSWIRE** ■

MONTREAL: Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VYVANSE® (lisdexamfetamine dimesylate capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents and adults.

LAVAL, QC: Labopharm Inc. today announced that Health Canada's Therapeutic Products Directorate (TPD) has approved OLEPTRO(TM) (trazodone hydrochloride Extended Release Tablets), a novel once-daily formulation of the antidepressant trazodone, for the symptomatic relief of Major Depressive Disorder (MDD) in adults. OLEPTRO(TM) acts as a serotonin antagonist reuptake inhibitor (SARI), providing physicians and patients in Canada with a new option in the treatment of MDD.

MISSISSAUGA, ON: Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new fixed-dose combination (FDC) therapy for the treatment of HIV. The new investigational regimen, known as 572-Trii, will combine the investigational integrase inhibitor S/GSK1349572 ('572) and ViiV Healthcare's combination nucleoside reverse transcriptase inhibitor (NRTI) Kivexa®/Epizcom® (ABC/3TC).

QUEBEC CITY: The Fonds de la recherche en santé du Québec (FRSQ), in partnership with the Ministère de la Santé et des Services sociaux (MSSS) and the pharmaceutical company Pfizer Canada, announces the first series of projects chosen in connection with the Pfizer-FRSQ-MSSS Chronic Disease Fund.

MISSISSAUGA, ON: GlaxoSmithKline Inc. (GSK) announced that Health Canada has approved Revolade™ (eltrombopag), for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

